Palisade Bio, Inc. announced on October 2, 2025, the closing of its previously announced underwritten public offering, which generated gross proceeds of approximately $138 million. This amount includes the full exercise of the underwriter’s over-allotment option to purchase additional shares of common stock.
The offering comprised 197,154,844 shares of common stock (or common stock equivalents) at a public offering price of $0.70 per share. This substantial financing is intended to support the upcoming Phase 2 clinical development program for PALI-2108 in Ulcerative Colitis.
The successful closing of this offering provides Palisade Bio with significant resources to accelerate its progress and execute a more robust development plan for its lead candidate. However, the large number of shares issued at $0.70 per share results in considerable dilution for existing shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.